Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Provided By GlobeNewswire

Last update: May 14, 2025

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.